Company Interview / QBiotics on a remission mission

Stephen Doyle from QBiotics shares his insights on their promising results from stage two clinical trials for soft tissue sarcoma treatment. The trials, conducted at Memorial Sloan Cancer Center, show 80% of patients present an objective tumour response, with 52% achieving complete tumour ablation. Patients maintained tumour remission for six months, providing hope for further advancements.

Stephen explains their lead treatment, an intratumoral injection that targets tumours directly, potentially offering systemic effects. This method allows for tumour reduction not only at the injection site but also elsewhere in the body. This innovative approach suggests a new pathway for vaccine-like cancer treatment.

QBiotics continues its research on other solid tumours, including head and neck cancers, with ongoing studies in Australia and the UK. Despite a promising pipeline, Stephen highlights the need for future funding rounds to support upcoming research projects.